A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes

BACKGROUND: The antihypertensive compound hydralazine is a known demethylating agent. This phase I study evaluated the tolerability and its effects upon DNA methylation and gene reactivation in patients with untreated cervical cancer. METHODS: Hydralazine was administered to cohorts of 4 patients at...

Descripción completa

Detalles Bibliográficos
Autores principales: Zambrano, Pilar, Segura-Pacheco, Blanca, Perez-Cardenas, Enrique, Cetina, Lucely, Revilla-Vazquez, Alma, Taja-Chayeb, Lucía, Chavez-Blanco, Alma, Angeles, Enrique, Cabrera, Gustavo, Sandoval, Karina, Trejo-Becerril, Catalina, Chanona-Vilchis, Jose, Duenas-González, Alfonso
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1131894/
https://www.ncbi.nlm.nih.gov/pubmed/15862127
http://dx.doi.org/10.1186/1471-2407-5-44

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1131894/
https://www.ncbi.nlm.nih.gov/pubmed/15862127
http://dx.doi.org/10.1186/1471-2407-5-44

Ejemplares similares